$SAVA Cassava Sciences Inc Long term PT 145 and higherNASDAQ:SAVA Cassava Sciences Inc
Long term PT 145 and higher
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and in